This review highlights #HER3 as a key #oncogenic driver shaped by #TumorMicroenvironment signals, stressing the need for predictive #biomarkers, novel ADCs, and combination strategies to boost HER3-targeted #cancer therapies. @cwru.bsky.social

#OpenAccess: doi.org/10.1016/j.ge...

HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors - OncoDaily HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors / Aaron Lisberg, ADC, Alex Spira, Alexander Starodub, American

HER3-Targeted Antibody-Drug Conjugate Shows Promise for Treatment-Resistant Solid Tumors
@ascocancer.bsky.social

oncodaily.com/insight/anti...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC #HER3 #SolidTumors #NSCLC #LungCancer #DB1310 #ASCO #ASCO2025

Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma

🥁🥁New article in EJNMMI: Expression of #SSTR2a, #FAP, #HER2 and #HER3 as potential radionuclide therapy targets in higher-grade #meningioma.
rdcu.be/eaSo6
@mj-mair.bsky.social @nathaliealbert.bsky.social @eanm.org

ICYMI in Cancer Discovery: Zenocutuzumab, a #HER2 x #HER3 #Bispecific Antibody, Is Effective Therapy for Tumors Driven by #NRG1 Gene Rearrangements - by Alison Schram and colleagues @mskcancercenter.bsky.social doi.org/10.1158/2159...